Home » Newsletters » BioWorld Science

BioWorld Science

April 1, 2020

View Archived Issues

How the eye cleans itself up

Selective TGF-beta inhibition helps checkpoint blockade

Cabpirin tablets approved in Japan

Positive topline data from phase I clinical study of BX-001

Hydroxychloroquine and azithromycin show efficacy in patients with COVID-19

HDE biomarkers to predict idiosyncratic drug-induced liver injury

Kissei Pharmaceutical discloses new Egl nine homolog 1 inhibitors

New RET inhibitors discovered at Array BioPharma

Common form of muscular dystrophy causes damage through hypoxia

China's NMPA clears IND for trials of NTRK/ROS1 inhibitor HG-030

CTL1 is a potential therapeutic target in glioma

Bristol-Myers Squibb discovers RIP-1 inhibitors

Cocrystal Pharma synthesizes influenza virus replication inhibitors

ViiV Healthcare presents new HIV replication inhibitors

Convalescent plasma shows benefit in patients with COVID-19 and ARDS

Akero reports data from phase IIa study of AKR-001 in NASH

Dicerna reports initial data from PHYOX 3 long-term extension study of nedosiran for PH

Kiniksa reports early evidence of treatment response with mavrilimumab in severe COVID-19 pneumonia

Influenza antiviral drug favipiravir begins phase III trial in Japan for COVID-19

InflaRx begins clinical trial of IFX-1 in patients with severe COVID-19 pneumonia

ProQR reports interim data from phase I/II study of QR-421a for Usher syndrome

Klus begins first-in-human study of TROP2-targeting ADC SKB-264 in advanced solid tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...